Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation
- PMID: 27448465
- DOI: 10.1016/j.sleep.2016.01.017
Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation
Abstract
A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation. Alternatively, if dopaminergic drugs are elected as initial treatment, then the daily dose should be as low as possible and not exceed that recommended for RLS/WED treatment. However, the physician should be aware that even low dose dopaminergics can cause augmentation. Patients with low iron stores should be given appropriate iron supplementation. Daily treatment by either medication should start only when symptoms have a significant impact on quality of life in terms of frequency and severity; intermittent treatment might be considered in intermediate cases. Treatment of existing augmentation should be initiated, where possible, with the elimination/correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). In cases of mild augmentation, dopamine agonist therapy can be continued by dividing or advancing the dose, or increasing the dose if there are breakthrough night-time symptoms. Alternatively, the patient can be switched to an α2δ ligand or rotigotine. For severe augmentation the patient can be switched either to an α2δ ligand or rotigotine, noting that rotigotine may also produce augmentation at higher doses with long-term use. In more severe cases of augmentation an opioid may be considered, bypassing α2δ ligands and rotigotine.
Keywords: Algorithm; Alpha 2 delta ligands; Augmentation; Dopamine agents; Prevention; Restless legs syndrome.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).Sleep Med Rev. 2018 Oct;41:50-60. doi: 10.1016/j.smrv.2018.01.001. Epub 2018 Jan 9. Sleep Med Rev. 2018. PMID: 29602660 Review.
-
The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.Sleep Med. 2013 Jul;14(7):675-84. doi: 10.1016/j.sleep.2013.05.016. Sleep Med. 2013. PMID: 23859128
-
Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.Postgrad Med. 2017 Sep;129(7):667-675. doi: 10.1080/00325481.2017.1360747. Epub 2017 Aug 18. Postgrad Med. 2017. PMID: 28818004 Review.
-
Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.Adv Pharmacol. 2019;84:187-205. doi: 10.1016/bs.apha.2019.02.003. Epub 2019 Mar 14. Adv Pharmacol. 2019. PMID: 31229171 Review.
-
Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.Sleep Med. 2007 Aug;8(5):520-30. doi: 10.1016/j.sleep.2007.03.022. Epub 2007 Jun 1. Sleep Med. 2007. PMID: 17544323
Cited by
-
Unveiling the pathophysiology of restless legs syndrome through transcriptome analysis.iScience. 2024 Mar 26;27(4):109568. doi: 10.1016/j.isci.2024.109568. eCollection 2024 Apr 19. iScience. 2024. PMID: 38617564 Free PMC article.
-
A survey-based approach on restless legs syndrome: practices and perspectives among Italian neurologists.J Neurol. 2024 Jul;271(7):4227-4236. doi: 10.1007/s00415-024-12356-7. Epub 2024 Apr 12. J Neurol. 2024. PMID: 38607430
-
Restless leg syndrome prevalence in epilepsy patients and its impact on quality of sleep.Sleep Biol Rhythms. 2022 Mar 24;20(3):413-420. doi: 10.1007/s41105-022-00386-5. eCollection 2022 Jul. Sleep Biol Rhythms. 2022. PMID: 38469425 Free PMC article.
-
Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study.CNS Drugs. 2024 Jan;38(1):45-54. doi: 10.1007/s40263-023-01055-y. Epub 2024 Jan 21. CNS Drugs. 2024. PMID: 38246901 Clinical Trial.
-
Spinal cord stimulation in severe pharmacoresistant restless legs syndrome-two case reports.Front Neurol. 2023 Nov 30;14:1219881. doi: 10.3389/fneur.2023.1219881. eCollection 2023. Front Neurol. 2023. PMID: 38099065 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials